why choose us

First received: May 04, 2023

Clinical Trial: Correction of Psoriatic T Cell Signatures by Deucravacitinib

Study Status: NOT_YET_RECRUITING

Recruit Status: NOT_YET_RECRUITING

Condition: Psoriasis Vulgaris

Study Type: INTERVENTIONAL


Official Title: Correction of Psoriatic T Cell Signatures by Deucravacitinib

Brief Summary: This study aims to assess cutaneous and blood immune cell function of patients with psoriasis before and after initiation of treatment with the Tyrosine kinase 2 (TYK2) blocker, deucravacitinib.

Read more